Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Capecitabine
Drug ID BADD_D00349
Description Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Indications and Usage For the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen. May also be used in combination with docetaxel for the treatment of metastatic breast cancer in patients who have failed to respond to, or recurred or relasped during or following anthracycline-containing chemotherapy. Capecitabine is used alone as an adjuvant therapy following the complete resection of primary tumor in patients with stage III colon cancer when monotherapy with fluroprymidine is preferred. The use or capecitabine in combination regimens for advanced gastric cancer is currently being investigated.
Marketing Status approved; investigational
ATC Code L01BC06
DrugBank ID DB01101
KEGG ID D01223
MeSH ID D000069287
PubChem ID 60953
TTD Drug ID D00HCQ
NDC Product Code 55111-893; 82920-001; 72205-007; 72485-205; 62331-043; 16714-467; 51407-640; 55111-496; 55111-497; 61269-475; 65162-844; 15308-0714; 54893-0002; 59651-205; 64980-277; 70756-815; 68001-487; 69097-949; 72205-006; 63482-099; 72969-094; 16729-072; 59923-721; 61269-470; 0054-0271; 69539-019; 0093-7473; 64980-276; 0054-0272; 69097-948; 72606-554; 53104-7618; 55512-0015; 0004-1100; 51407-639; 67877-459; 68001-488; 69539-020; 35369-0010; 16729-073; 51407-096; 62756-238; 62756-239; 65162-843; 67877-458; 59651-204; 72485-204; 72606-555; 49452-1713; 68554-0033; 0004-1101; 0093-7474; 51407-095; 60687-149; 0378-2511; 70756-816; 53183-4009; 54245-7014; 65129-1241; 81955-0001; 16714-468; 59923-722
UNII 6804DJ8Z9U
Synonyms Capecitabine | N(4)-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine | Xeloda
Chemical Information
Molecular Formula C15H22FN3O6
CAS Registry Number 154361-50-9
SMILES CCCCCOC(=O)NC1=NC(=O)N(C=C1F)C2C(C(C(O2)C)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Plantar erythema23.03.06.0120.000302%Not Available
Madarosis23.02.02.004; 06.06.04.0100.000470%Not Available
Dyschezia07.02.03.0050.000112%Not Available
Photodermatosis23.03.09.0040.000246%Not Available
Exercise tolerance decreased08.01.03.0360.000112%Not Available
Malignant neoplasm progression16.16.01.0050.005932%Not Available
Enterocutaneous fistula07.11.05.005; 23.07.04.0170.000168%Not Available
Rhinalgia22.12.03.0200.000381%Not Available
Acute coronary syndrome02.02.02.015; 24.04.04.0110.002015%Not Available
Necrotising colitis07.08.01.0130.000112%Not Available
Metastases to peritoneum16.22.02.008; 07.21.03.0030.000448%Not Available
Infusion related reaction12.02.05.009; 10.01.01.017; 08.01.03.002--
Haemodynamic instability24.03.02.0060.000336%Not Available
Gastrointestinal hypomotility07.02.02.0050.000112%Not Available
Eyelid margin crusting23.03.03.029; 06.04.04.0050.000571%Not Available
Ear discomfort04.03.01.005--Not Available
Lymphatic disorder01.09.01.0030.000112%Not Available
Colorectal cancer metastatic16.13.01.005; 07.21.01.0050.000224%Not Available
Adenocarcinoma pancreas16.13.10.002; 07.21.09.0030.000280%Not Available
Drug tolerance decreased08.06.01.0240.000112%Not Available
Musculoskeletal stiffness15.03.05.027--Not Available
Protein urine present13.13.02.006--Not Available
Epigastric discomfort07.01.02.0040.000381%Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Organ failure08.01.03.0410.000168%Not Available
Epidermolysis23.03.01.014; 10.04.02.0170.000112%Not Available
Walking disability26.01.01.009--Not Available
Febrile bone marrow aplasia08.05.02.005; 01.03.03.0070.000504%Not Available
Skin swelling23.03.03.0390.000280%Not Available
Secretion discharge08.01.03.0190.000112%Not Available
The 22th Page    First    Pre   22 23 24 25 26    Next   Last    Total 31 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene